Premium
Immediate moxifloxacin hypersensitivity: Is there more than currently meets the eye?
Author(s) -
Van Gasse A. L.,
Sabato V.,
Uyttebroek A. P.,
Elst J.,
Faber M. A.,
Hagendorens M. M.,
Mertens C.,
Bridts C. H.,
De Clerck L. S.,
Ebo D. G.
Publication year - 2017
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.13236
Subject(s) - moxifloxacin , medicine , basophil activation , histamine , basophilic , immunology , basophil , pharmacology , immunoglobulin e , antibiotics , pathology , biology , microbiology and biotechnology , antibody
Immediate drug hypersensitivity reactions ( IDHR ) to moxifloxacin constitute a pathomechanistic conundrum and a diagnostic challenge. Our objective was to study whether simultaneous phenotyping and quantification of histamine release might add to our knowledge about the basophil activation properties of moxifloxacin and constitute a reliable diagnostic aid. Fifteen patients with an IDHR to moxifloxacin and nine moxifloxacin challenged controls were selected. All had a basophil activation test ( BAT ) with moxifloxacin. Flow cytometric analysis of basophil responses implied labeling for CD 63, CD 203c, and intracellular histamine. Unlike tolerant challenged controls, basophilic upregulation of CD 203c in response to moxifloxacin was observed in seven of 15 patients. Only two of these seven patients demonstrated appearance of CD 63 and release of histamine. In the remainder eight patients, no basophil responses were demonstrable. In conclusion, immediate hypersensitivity to moxifloxacin might involve mechanisms difficult to capture by traditional CD 63‐/ CD 203c‐based BAT . Deciphering the complexity of quinolone IDHR seems mandatory.